Angiogenesis Targeting via Tumor-Specific Vascular Markers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for targeting angiogenesis in cancer therapy are limited by a lack of understanding of the specific genes expressed in tumor blood vessels, which hampers the development of effective molecularly targeted antiangiogenic agents.
Innovation Solution
Identification of polynucleotides and polypeptides with increased expression in tumor blood vessels, and the use of inhibitors thereof, to regulate angiogenesis and diagnose/treat angiogenesis-related diseases such as cancer, involving methods to decrease or increase their expression/activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If VEGF is targeted with bevacizumab, then angiogenesis is inhibited, but the complexity of identifying additional tumor-specific vascular genes increases
Solution Approach 1:
The patent segments the angiogenesis pathway into multiple distinct gene targets (VEGF, PDGF, FGF, and novel tumor-specific genes like SFRP2, JAK3, FAP). By dividing the complex angiogenic process into separate molecular targets, the invention enables selective inhibition of individual genes while maintaining overall therapeutic efficacy, thus managing complexity through systematic categorization of targets.
Solution Approach 2:
The patent introduces tumor-specific vascular markers (TEMs) such as SFRP2, JAK3, and FAP as intermediary targets that mediate between the tumor microenvironment and angiogenesis. These markers serve as actionable intermediaries that are specifically expressed in tumor vessels but not normal tissue, providing a bridge for selective targeting without affecting physiological angiogenesis.
2Adaptability or versatility
If multiple tumor-specific vascular genes are identified, then therapeutic targeting options increase, but the difficulty of detecting and measuring specific gene expression increases
Solution Approach 1:
The patent applies local quality by identifying and measuring specific gene expressions (SFRP2, JAK3, FAP) that are locally enriched in tumor vascular compartments. Rather than attempting to detect all angiogenic genes systemically, the invention focuses measurement efforts on specific markers that are locally expressed in tumor vessels, making detection feasible through techniques like laser capture microdissection followed by gene expression analysis.
Solution Approach 2:
The patent creates a profile or copy of tumor vascular gene expression patterns by analyzing multiple genes simultaneously (VEGF, PDGF, FGF, and novel markers). This multi-gene expression profile serves as a diagnostic copy that can be measured in patient samples to identify tumor-specific vascular characteristics, simplifying the detection process while maintaining comprehensive targeting options.
3Measurement precision
If tissue dissociation and cell immunopurification are used to isolate endothelial cells, then gene expression analysis accuracy improves, but the loss of time and complexity increases
Solution Approach 1:
The patent performs preliminary action by pre-characterizing tumor-specific vascular markers (SFRP2, JAK3, FAP) through laser capture microdissection of vessel cells from tumor tissues. This preliminary identification of markers allows subsequent simpler methods (such as immunohistochemistry or RNA in situ hybridization) to be used for detecting these genes in patient samples, reducing the time required for cell isolation while maintaining measurement precision.
Data Source
AI summary
The present invention relates to the identification of polynucleotides and polypeptides having increased expression in tumor blood vessels. The invention further relates to the use of the identified polynucleotides and polypeptides, and inhibitors of the polynucleotides and polypeptides, in the regulation of angiogenesis and the diagnosis and treatment of angiogenesis-related diseases such as cancer.